Some lymphomas brought on by hepatitis B virus
The hepatitis B virus, already implicated in liver cancer, may also be involved in causing non-Hodgkin's lymphoma, according to an enormous new retrospective study from South Korea.
Researchers looked at the records of over 600,000 South Koreans from the early 1990s, prior to the launch of a vaccination program against hepatitis B and found that those carrying the virus had an increased risk of developing an NHL, specifically diffuse large B-cell lymphoma, compared to those without the virus.
CONCLUSIONS
Researchers speculated that in people with either hepatitis B or C, the immune system may become overstimulated trying to fight off the liver infection causes by these viruses, leading to the lymphoma.
HEMATOLOGICAL CANCER TYPE(S)
Diffuse large B-cell lymphoma (DLBCL)
WHERE WAS THIS RESEARCH PUBLISHED?
The Lancet Oncology
Citation
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
